воскресенье, 5 марта 2017 г.

AbbVie: Humira Continues To Be Attacked

AbbVie: Humira Continues To Be Attacked


Kirin Biologics brought a lawsuit to the UK High Court of Justice seeking a judgment against AbbVie and its dosing protocols. Shares of AbbVie move as its blockbuster Humira moves because the product accounts for roughly 60% of sales.



from Biotech News